CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar. The event is scheduled for Wednesday, August 28, 2024, at 3:20 PM ET.
John Climaco, the company's Chief Executive Officer, will present and discuss recent corporate developments during the webinar. This presentation offers an opportunity for investors and interested parties to gain insights into CNS Pharmaceuticals' latest advancements and future plans in the field of cancer treatment.
Participants can register for the event through the provided registration link, allowing them to join the live webcast and learn more about CNS Pharmaceuticals' innovative approaches to addressing primary and metastatic cancers in the brain and central nervous system.
CNS Pharmaceuticals (NASDAQ: CNSP), un'azienda biofarmaceutica focalizzata sullo sviluppo di nuovi trattamenti per i tumori del cervello e del sistema nervoso centrale, ha annunciato la sua partecipazione al LIVE! con Webull Corporate Connect: Webinar Virtuale sugli Investimenti Biotech. L'evento è programmato per mercoledì 28 agosto 2024, alle 15:20 ET.
John Climaco, Amministratore Delegato dell'azienda, presenterà e discuterà i recenti sviluppi aziendali durante il webinar. Questa presentazione offre l'opportunità agli investitori e ai soggetti interessati di ottenere informazioni sui più recenti progressi e piani futuri di CNS Pharmaceuticals nel settore del trattamento dei tumori.
I partecipanti possono registrarsi per l'evento tramite il link di registrazione fornito, consentendo loro di unirsi al webcast dal vivo e scoprire di più sui nuovi approcci innovativi di CNS Pharmaceuticals per affrontare i tumori primari e metastatici nel cervello e nel sistema nervoso centrale.
CNS Pharmaceuticals (NASDAQ: CNSP), una empresa biofarmacéutica centrada en el desarrollo de tratamientos innovadores para los cánceres del cerebro y del sistema nervioso central, ha anunciado su participación en el LIVE! con Webull Corporate Connect: Webinar Virtual de Inversión en Biotecnología. El evento está programado para miércoles, 28 de agosto de 2024, a las 3:20 PM ET.
John Climaco, el Director Ejecutivo de la empresa, presentará y discutirá los recientes desarrollos corporativos durante el webinar. Esta presentación ofrece una oportunidad para que los inversores y partes interesadas obtengan información sobre los últimos avances y planes futuros de CNS Pharmaceuticals en el campo del tratamiento del cáncer.
Los participantes pueden registrarse para el evento a través del enlace de registro proporcionado, lo que les permite unirse a la transmisión en vivo y aprender más sobre los enfoques innovadores de CNS Pharmaceuticals para tratar cánceres primarios y metastásicos en el cerebro y el sistema nervioso central.
CNS Pharmaceuticals (NASDAQ: CNSP)는 뇌 및 중추신경계 암 치료를 위한 새로운 치료법 개발에 주력하는 바이오 제약 회사로, 라이브! 웹울과 함께하는 기업 연결: 가상 생명공학 투자 웨비나에 참여한다고 발표했습니다. 이 행사는 2024년 8월 28일 수요일, 오후 3시 20분 ET에 예정되어 있습니다.
회사의 CEO인 존 클리마코가 웨비나 동안 최근 기업 발전 사항을 발표하고 논의할 예정입니다. 이 발표는 투자자와 관심 있는 관계자들에게 CNS Pharmaceuticals의 최신 발전 상황과 향후 암 치료 계획에 대한 통찰력을 제공할 기회를 제공합니다.
참가자는 제공된 등록 링크를 통해 행사에 등록할 수 있으며, 이를 통해 라이브 웹캐스트에 참여하고 CNS Pharmaceuticals의 뇌 및 중추신경계의 원발성 및 전이성 암을 해결하기 위한 혁신적인 접근법에 대해 더 많이 배울 수 있습니다.
CNS Pharmaceuticals (NASDAQ: CNSP), une entreprise biopharmaceutique spécialisée dans le développement de nouveaux traitements pour les cancers du cerveau et du système nerveux central, a annoncé sa participation au LIVE! avec Webull Corporate Connect : Webinaire d'Investissement Virtuel en Biotechnologie. L'événement est prévu pour le mercredi 28 août 2024, à 15h20 ET.
John Climaco, le directeur général de l'entreprise, présentera et discutera des récents développements de l'entreprise lors du webinaire. Cette présentation offre une opportunité pour les investisseurs et les parties intéressées d'obtenir des informations sur les derniers progrès et les plans futurs de CNS Pharmaceuticals dans le domaine du traitement du cancer.
Les participants peuvent s'inscrire à l'événement via le lien d'inscription fourni, leur permettant de rejoindre le webinaire en direct et d'en apprendre davantage sur les approches innovantes de CNS Pharmaceuticals pour traiter les cancers primaires et métastatiques du cerveau et du système nerveux central.
CNS Pharmaceuticals (NASDAQ: CNSP), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuartiger Behandlungen für Hirn- und zentrale Nervensystemtumoren konzentriert, hat seine Teilnahme am LIVE! mit Webull Corporate Connect: Virtueller Biotech-Investment-Webinar bekannt gegeben. Die Veranstaltung ist für Mittwoch, den 28. August 2024, um 15:20 Uhr ET angesetzt.
John Climaco, der Chief Executive Officer des Unternehmens, wird während des Webinars über aktuelle Unternehmensentwicklungen präsentieren und diskutieren. Diese Präsentation bietet Investoren und interessierten Parteien die Gelegenheit, Einblicke in die neuesten Fortschritte und zukünftigen Pläne von CNS Pharmaceuticals im Bereich der Krebsbehandlung zu gewinnen.
Teilnehmer können sich über den bereitgestellten Registrierungslink für die Veranstaltung anmelden, um an dem Live-Webcast teilzunehmen und mehr über die innovativen Ansätze von CNS Pharmaceuticals zur Bekämpfung von primären und metastasierten Tumoren im Gehirn und zentralen Nervensystem zu erfahren.
- None.
- None.
Live webcast on Wednesday, August 28th at 3:20 PM ET
HOUSTON, TX / ACCESSWIRE / August 27, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, August 28, 2024 at 3:20 PM ET.
Conference Details:
Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Date/Time: Wednesday, August 28, 2024 at 3:20 PM ET
Presenter: John Climaco, Chief Executive Officer
Registration Link: HERE
About Webull Financial
Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscores the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates, they combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
When is CNS Pharmaceuticals (CNSP) presenting at the Webull Corporate Connect Webinar?
Who will be presenting for CNS Pharmaceuticals (CNSP) at the Webull Corporate Connect Webinar?
What is the focus of CNS Pharmaceuticals' (CNSP) research and development?
How can investors participate in the CNS Pharmaceuticals (CNSP) presentation at the Webull Corporate Connect Webinar?
